Ibuprofen Farmalider
Oral Suspension 20 mg/ml – Non-Steroidal Anti-Inflammatory Drug (NSAID)
Ibuprofen Farmalider is a prescription oral suspension containing ibuprofen 20 mg/ml, belonging to the non-steroidal anti-inflammatory drug (NSAID) class. It is used to relieve mild to moderate pain, reduce inflammation, and lower fever in adults and children. The liquid formulation makes it particularly suitable for patients who have difficulty swallowing tablets, including young children and elderly patients.
Quick Facts
Key Takeaways
- Ibuprofen Farmalider is a liquid NSAID formulation (20 mg/ml) used for pain relief, inflammation reduction, and fever management in adults and children.
- The oral suspension form is ideal for pediatric patients and individuals who cannot swallow tablets, offering flexible and accurate dosing.
- Use the lowest effective dose for the shortest duration to minimize the risk of gastrointestinal, cardiovascular, and renal side effects.
- Avoid during the third trimester of pregnancy and use with caution alongside anticoagulants, ACE inhibitors, lithium, and other NSAIDs.
- Always shake the bottle well before use and measure doses accurately with the provided oral syringe or measuring device.
What Is Ibuprofen Farmalider and What Is It Used For?
Ibuprofen Farmalider belongs to the non-steroidal anti-inflammatory drug (NSAID) class, a widely used group of medications that reduce pain, inflammation, and fever. The active ingredient, ibuprofen, is a propionic acid derivative that has been used in clinical medicine for over five decades and is recognized by the World Health Organization (WHO) as an essential medicine.
The medication is formulated as an oral suspension at a concentration of 20 mg/ml, making it particularly well-suited for patients who have difficulty swallowing solid dosage forms. This includes young children, elderly patients, and individuals with conditions affecting the oropharynx or esophagus. The liquid formulation also allows for more precise dose adjustments based on body weight, which is especially important in pediatric care.
Ibuprofen exerts its therapeutic effects by non-selectively inhibiting both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes. These enzymes are responsible for converting arachidonic acid into prostaglandins, which are lipid mediators that play key roles in inflammation, pain sensitization, and thermoregulation. By reducing prostaglandin synthesis, ibuprofen decreases the cardinal signs of inflammation (pain, swelling, redness, and heat) and lowers elevated body temperature.
Common Indications
Ibuprofen Farmalider is indicated for the symptomatic treatment of a range of conditions. Your prescribing physician may recommend it for one or more of the following:
- Mild to moderate pain: Including headache, dental pain, menstrual pain (dysmenorrhea), post-operative pain, musculoskeletal pain, and pain associated with soft tissue injuries such as sprains and strains.
- Fever (pyrexia): Reduction of fever in both adults and children, including fever following immunization in infants over 3 months of age (weighing more than 5 kg).
- Inflammatory conditions: Symptomatic relief in conditions such as rheumatoid arthritis, juvenile idiopathic arthritis, osteoarthritis, and other musculoskeletal disorders with an inflammatory component.
- Childhood febrile illness: The oral suspension formulation is commonly prescribed for managing fever and pain in pediatric patients, given its ease of administration and dosing flexibility.
It is important to understand that Ibuprofen Farmalider treats symptoms rather than the underlying cause of disease. While it is highly effective at controlling pain, inflammation, and fever, it does not modify the progression of chronic inflammatory diseases such as rheumatoid arthritis. For long-term inflammatory conditions, your physician may combine it with disease-modifying agents. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) both recommend using NSAIDs at the lowest effective dose for the shortest duration consistent with individual treatment goals.
What Should You Know Before Taking Ibuprofen Farmalider?
Before starting any NSAID therapy, it is essential to have a thorough discussion with your healthcare provider about your medical history, current medications, and individual risk factors. Ibuprofen, like all NSAIDs, carries specific risks that must be balanced against its therapeutic benefits. The decision to use this medication should be based on a careful assessment of your particular clinical situation.
Contraindications
Ibuprofen Farmalider must not be used in the following situations:
- Hypersensitivity: Known allergy to ibuprofen, aspirin, or any other NSAID. This includes patients who have experienced asthma, urticaria (hives), rhinitis, or angioedema triggered by aspirin or other NSAIDs (sometimes referred to as the "aspirin triad" or Samter's triad).
- Active gastrointestinal bleeding or ulceration: Patients with active peptic ulcer disease, gastrointestinal hemorrhage, or a history of recurrent GI bleeding or perforation related to previous NSAID therapy.
- Severe hepatic failure: Patients with severe liver impairment (Child-Pugh class C).
- Severe renal failure: Patients with estimated glomerular filtration rate (eGFR) below 30 ml/min/1.73m².
- Severe heart failure: Patients with NYHA class IV heart failure.
- Third trimester of pregnancy: Use is contraindicated after 28 weeks of gestation due to the risk of premature closure of the fetal ductus arteriosus and potential inhibition of uterine contractions.
- Cerebrovascular bleeding: Active or recent intracranial hemorrhage.
Warnings and Precautions
Special care and close medical monitoring are required in patients with the following conditions or risk factors:
- Cardiovascular risk: NSAIDs may increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, particularly with long-term use or at higher doses. Patients with established cardiovascular disease, hypertension, hyperlipidemia, diabetes mellitus, or those who smoke are at elevated risk. The European Society of Cardiology (ESC) recommends avoiding NSAIDs when possible in patients with established cardiovascular disease.
- Gastrointestinal risk: All NSAIDs can cause serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Elderly patients, those with a history of peptic ulcer disease, and patients taking concurrent anticoagulants, corticosteroids, or selective serotonin reuptake inhibitors (SSRIs) are at greatest risk. Consider co-prescribing a proton pump inhibitor (PPI) for at-risk patients.
- Renal impairment: Ibuprofen can reduce renal blood flow through inhibition of renal prostaglandin synthesis. This may lead to fluid retention, edema, and worsening of kidney function, especially in patients with pre-existing renal compromise, congestive heart failure, or those taking diuretics or ACE inhibitors. Monitor renal function regularly.
- Hepatic impairment: Use with caution in patients with mild to moderate liver disease. Monitor liver function tests periodically. Discontinue if abnormal liver function persists or worsens.
- Asthma: Approximately 8–20% of asthmatic patients may experience NSAID-exacerbated respiratory disease. Use with extreme caution in patients with a history of bronchial asthma.
- Elderly patients: Increased susceptibility to adverse effects, particularly gastrointestinal bleeding and renal impairment. Use the lowest effective dose and monitor closely.
- Coagulation disorders: Ibuprofen inhibits platelet aggregation and may prolong bleeding time. Use with caution in patients with bleeding disorders or those undergoing surgical procedures.
Seek immediate medical attention if you experience signs of gastrointestinal bleeding (black or tarry stools, vomiting blood), cardiovascular events (chest pain, shortness of breath, weakness on one side of the body), or severe allergic reactions (swelling of the face, lips, tongue, or throat, difficulty breathing). Discontinue Ibuprofen Farmalider and contact your healthcare provider immediately.
Pregnancy and Breastfeeding
The use of Ibuprofen Farmalider during pregnancy requires careful consideration at each stage:
- First trimester (weeks 1–12): Some epidemiological data suggest a possible increased risk of miscarriage and cardiac malformations with NSAID use during early pregnancy, although the absolute risk is low. Use only if clearly necessary and at the lowest effective dose for the shortest duration.
- Second trimester (weeks 13–27): Use should be avoided unless clearly necessary. If used, treatment should be as brief as possible and at the lowest effective dose.
- Third trimester (weeks 28–40): Contraindicated. NSAIDs may cause premature closure of the ductus arteriosus in the fetus, oligohydramnios (reduced amniotic fluid due to fetal renal impairment), and inhibition of uterine contractions, potentially prolonging labor.
Breastfeeding: Ibuprofen is excreted in breast milk in very small quantities (less than 1% of the maternal dose). Due to its short half-life and low milk concentrations, ibuprofen is generally considered compatible with breastfeeding by the American Academy of Pediatrics (AAP) and the WHO. However, it is advisable to consult your healthcare provider before use and to take it immediately after nursing to minimize infant exposure.
How Does Ibuprofen Farmalider Interact with Other Drugs?
Drug interactions with ibuprofen can be clinically significant and may lead to increased risk of adverse effects or reduced therapeutic efficacy of either the interacting drug or ibuprofen itself. The following table summarizes the most important drug interactions. This is not an exhaustive list, and patients should always consult their prescriber or pharmacist before combining medications.
Major Interactions
| Interacting Drug | Effect | Clinical Recommendation |
|---|---|---|
| Warfarin / Anticoagulants | Increased risk of gastrointestinal and other bleeding due to combined antiplatelet and anticoagulant effects | Avoid combination if possible. If unavoidable, monitor INR closely and watch for signs of bleeding. Consider gastroprotection with a PPI. |
| Aspirin (low-dose) | Ibuprofen may interfere with the antiplatelet effect of low-dose aspirin, potentially reducing its cardioprotective benefit | Take aspirin at least 30 minutes before or 8 hours after ibuprofen. Discuss alternatives with your physician if taking aspirin for cardiovascular protection. |
| Methotrexate | NSAIDs reduce renal clearance of methotrexate, leading to elevated plasma levels and increased risk of toxicity (myelosuppression, mucositis) | Avoid concurrent use with high-dose methotrexate. With low-dose methotrexate, use with caution, monitor blood counts and renal function closely. |
| Lithium | NSAIDs reduce renal lithium excretion, increasing plasma lithium levels and risk of lithium toxicity | Monitor lithium levels closely when initiating, adjusting, or discontinuing ibuprofen. Dose adjustment of lithium may be required. |
| ACE Inhibitors / ARBs | Reduced antihypertensive effect and increased risk of acute kidney injury, particularly in volume-depleted patients | Monitor blood pressure and renal function. Ensure adequate hydration. Consider alternative analgesic if possible. |
Minor Interactions
| Interacting Drug | Effect | Clinical Recommendation |
|---|---|---|
| SSRIs (e.g., fluoxetine, sertraline) | Increased risk of gastrointestinal bleeding due to reduced platelet serotonin uptake combined with NSAID effects | Use with caution. Consider gastroprotection with a PPI, especially in elderly patients or those with GI risk factors. |
| Corticosteroids | Increased risk of gastrointestinal ulceration and bleeding | Co-prescribe a PPI for gastroprotection. Use the lowest effective dose of both agents. |
| Diuretics (thiazides, loop) | Reduced diuretic and antihypertensive effect. Increased risk of acute kidney injury with dehydration. | Monitor fluid balance, blood pressure, and renal function. Ensure adequate hydration. |
| Ciclosporin / Tacrolimus | Increased risk of nephrotoxicity | Monitor renal function closely. Consider alternative analgesic where possible. |
| Quinolone antibiotics | Possible increased risk of seizures in susceptible patients | Use with caution. Be aware of potential CNS effects, especially in patients with epilepsy or other seizure disorders. |
| Other NSAIDs | No additional therapeutic benefit but significantly increased risk of adverse effects (GI bleeding, renal impairment) | Avoid concurrent use of multiple NSAIDs. Switch rather than combine. |
Always bring a complete list of your current medications (including over-the-counter products, vitamins, and herbal supplements) to every healthcare appointment. Some over-the-counter cold and flu remedies already contain ibuprofen or other NSAIDs, and inadvertent double-dosing can increase the risk of serious side effects.
What Is the Correct Dosage of Ibuprofen Farmalider?
Dosing of Ibuprofen Farmalider should be individualized based on the patient's age, weight, severity of symptoms, and clinical response. The fundamental principle endorsed by the EMA, FDA, and WHO is to use the lowest effective dose for the shortest duration necessary to control symptoms. The oral suspension contains 20 mg of ibuprofen per milliliter, and each dose should be measured accurately using the oral syringe or measuring device provided with the product.
Adults
Adult Dosing (age 12 years and above)
- Mild to moderate pain / Fever: 200–400 mg (10–20 ml) every 6–8 hours as needed.
- Maximum self-medication dose: 1200 mg (60 ml) per day.
- Maximum prescription dose (under medical supervision): Up to 2400 mg (120 ml) per day in divided doses for inflammatory conditions.
- Take with or after food to reduce gastrointestinal irritation.
- Duration: For self-medication, do not exceed 3 days for fever or 5 days for pain without medical advice.
Children
Pediatric Dosing (children over 3 months, weighing over 5 kg)
- Standard dose: 5–10 mg/kg body weight per dose, administered every 6–8 hours.
- Maximum daily dose: 20–30 mg/kg body weight, divided into 3–4 doses.
- Post-immunization fever (infants 3–5 months): 50 mg (2.5 ml) followed by a second 50 mg dose after 6 hours if needed. Maximum 2 doses in 24 hours. Consult a physician if fever persists.
| Body Weight | Age (approximate) | Single Dose (ml) | Max Daily Dose |
|---|---|---|---|
| 5–7 kg | 3–6 months | 2.5 ml (50 mg) | 7.5 ml (150 mg) |
| 8–10 kg | 6–12 months | 2.5 ml (50 mg) | 10 ml (200 mg) |
| 11–15 kg | 1–3 years | 5 ml (100 mg) | 15 ml (300 mg) |
| 16–20 kg | 4–6 years | 5–7.5 ml (100–150 mg) | 20 ml (400 mg) |
| 21–30 kg | 7–9 years | 7.5–10 ml (150–200 mg) | 30 ml (600 mg) |
| 31–40 kg | 10–12 years | 10–15 ml (200–300 mg) | 40 ml (800 mg) |
Elderly
Elderly Patients (65 years and above)
- Start with the lowest recommended dose and increase gradually if needed.
- Maximum recommended dose: 1200 mg (60 ml) per day unless under close medical supervision.
- Monitor renal function, hepatic function, and complete blood count regularly.
- Co-prescribe a PPI for gastroprotection, especially if treatment exceeds a few days.
- Be alert for signs of GI bleeding (which may present with fewer symptoms in elderly patients).
Missed Dose
If you miss a dose of Ibuprofen Farmalider, take it as soon as you remember unless it is almost time for your next scheduled dose. In that case, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one, as this increases the risk of adverse effects, particularly gastrointestinal and renal complications.
Overdose
Symptoms of ibuprofen overdose may include nausea, vomiting, epigastric pain, drowsiness, headache, tinnitus, and in severe cases, gastrointestinal bleeding, metabolic acidosis, renal failure, seizures, and coma. There is no specific antidote for ibuprofen overdose. Treatment is symptomatic and supportive. If overdose is suspected, contact your local poison control center or emergency services immediately. Early gastric decontamination (activated charcoal) may be considered if ingestion occurred within the preceding hour.
What Are the Side Effects of Ibuprofen Farmalider?
Like all NSAIDs, Ibuprofen Farmalider can cause side effects, although not everyone will experience them. The frequency and severity of adverse effects generally increase with higher doses and longer treatment duration. The following classification uses standard pharmacovigilance frequency categories as defined by the Council for International Organizations of Medical Sciences (CIOMS) and the EMA.
If you experience any side effects not listed below, or if any listed side effects become severe or persistent, contact your healthcare provider promptly. Serious side effects require immediate medical attention.
Very Common
- Dyspepsia (indigestion, heartburn)
- Nausea
- Abdominal pain or discomfort
Common
- Diarrhea
- Vomiting
- Flatulence and bloating
- Constipation
- Headache
- Dizziness
- Skin rash
- Fatigue
- Fluid retention and mild edema
Uncommon
- Gastric or duodenal ulceration
- Gastrointestinal bleeding (melena, hematemesis)
- Elevated liver enzymes (AST, ALT)
- Urticaria (hives)
- Tinnitus (ringing in the ears)
- Visual disturbances
- Insomnia
- Anxiety or nervousness
- Impaired renal function
Rare
- Anaphylaxis (severe allergic reaction)
- Stevens-Johnson syndrome / Toxic epidermal necrolysis
- Aseptic meningitis (especially in patients with SLE)
- Severe hepatic reactions (hepatitis, jaundice)
- Acute renal failure
- Interstitial nephritis
- Agranulocytosis, aplastic anemia, thrombocytopenia
- Cardiovascular thrombotic events (myocardial infarction, stroke)
- Severe bronchospasm in susceptible patients
- Gastrointestinal perforation
Contact emergency services or go to the nearest emergency department if you experience: signs of GI bleeding (black tarry stools, vomiting blood or material that looks like coffee grounds), signs of a severe allergic reaction (difficulty breathing, swelling of face/lips/tongue/throat), chest pain or signs of stroke (sudden weakness, difficulty speaking, vision changes), or signs of severe skin reactions (widespread rash with blistering or peeling).
A comprehensive meta-analysis published in The Lancet (Coxib and traditional NSAID Trialists' Collaboration, 2013) involving over 353,000 participants found that ibuprofen at typical analgesic doses (up to 1200 mg/day) was associated with a lower cardiovascular risk compared to higher doses. The British National Formulary (BNF) and the National Institute for Health and Care Excellence (NICE) both emphasize that ibuprofen remains one of the safest NSAIDs when used at recommended doses for short durations.
How Should You Store Ibuprofen Farmalider?
Proper storage of Ibuprofen Farmalider is essential to maintain its efficacy, safety, and palatability throughout its shelf life. Pharmaceutical suspensions are particularly sensitive to environmental conditions because the active ingredient is dispersed rather than dissolved, and changes in temperature or light can affect both the chemical stability of ibuprofen and the physical integrity of the suspension.
Follow these storage guidelines to ensure your medication remains safe and effective:
- Temperature: Store at room temperature, not exceeding 25°C (77°F). Avoid exposing the product to extreme heat (e.g., leaving it in a car during summer) or extreme cold.
- Light protection: Keep the bottle in its original outer carton to protect from light, as ibuprofen can undergo photodegradation when exposed to ultraviolet radiation.
- Moisture: Store in a dry place. Keep the bottle tightly closed when not in use to prevent moisture ingress, which can promote microbial growth in the suspension.
- Freezing: Do not freeze the suspension, as this can irreversibly alter the formulation's physical properties, making it difficult to re-disperse the active ingredient uniformly.
- Shelf life after opening: Once opened, use within the timeframe specified on the product packaging (typically 6 months). Mark the date of opening on the bottle for reference.
- Shake well before each use: Oral suspensions settle over time. Thorough shaking ensures a uniform distribution of the active ingredient and accurate dosing.
- Child safety: Store in a location inaccessible to children. The pleasant taste of oral suspensions can make them attractive to children, posing a risk of accidental overdose.
- Disposal: Do not dispose of unused medication via household waste or wastewater. Return unused or expired medication to a pharmacy for safe disposal in accordance with local regulations.
What Does Ibuprofen Farmalider Contain?
Understanding the complete composition of your medication is important, particularly if you have known allergies or intolerances to specific excipients (inactive ingredients). The following information describes the typical composition of Ibuprofen Farmalider oral suspension. Exact excipient formulations may vary slightly between manufacturers and batches; always refer to the patient information leaflet supplied with your specific product for the most accurate information.
Active Ingredient
- Ibuprofen: 20 mg per milliliter. Ibuprofen is a racemic mixture of (R)-ibuprofen and (S)-ibuprofen. The (S)-enantiomer (also called dexibuprofen) is the pharmacologically active form responsible for COX inhibition. After oral administration, approximately 60% of the inactive (R)-form is converted to the active (S)-form in vivo.
Excipients (Inactive Ingredients)
Oral suspensions typically contain the following categories of excipients to ensure a stable, palatable, and easy-to-use product:
- Suspending agents: Such as xanthan gum or microcrystalline cellulose, which keep the ibuprofen particles evenly distributed throughout the liquid.
- Sweeteners: Such as sucrose, maltitol, or sorbitol to improve palatability, particularly important for pediatric formulations. Patients with diabetes or hereditary fructose intolerance should check whether sucrose or sorbitol is present.
- Flavoring agents: Typically fruit flavors (strawberry, orange) to mask the bitter taste of ibuprofen and improve patient compliance.
- Preservatives: Such as sodium benzoate or potassium sorbate to prevent microbial contamination, especially after the bottle has been opened.
- Buffer systems: Such as citric acid and sodium citrate to maintain the pH of the suspension within the optimal range for stability and taste.
- Purified water: The vehicle (base liquid) of the suspension.
Ibuprofen Farmalider oral suspension is typically gluten-free and does not contain lactose. However, some formulations may contain maltitol, sorbitol, or other sugar alcohols. Patients with hereditary fructose intolerance should not take formulations containing sorbitol. Always check the patient information leaflet for your specific product or consult your pharmacist if you have known allergies or dietary restrictions.
Frequently Asked Questions
Ibuprofen Farmalider is an oral suspension containing 20 mg/ml of ibuprofen, a non-steroidal anti-inflammatory drug (NSAID). It is used to treat mild to moderate pain (headache, dental pain, menstrual pain, musculoskeletal pain), reduce inflammation in conditions such as arthritis, and lower fever in adults and children over 3 months of age weighing at least 5 kg. The liquid form makes it especially convenient for children and patients who cannot swallow tablets.
The most frequently reported side effects are gastrointestinal in nature: nausea, indigestion (dyspepsia), abdominal pain, and diarrhea. Headache, dizziness, and mild fluid retention may also occur. These side effects are generally mild and often resolve with continued use or dose reduction. Serious side effects such as GI bleeding, peptic ulceration, and cardiovascular events are less common but can occur, particularly with prolonged use or at higher doses.
Yes, Ibuprofen Farmalider oral suspension is suitable for children over 3 months of age who weigh at least 5 kg. Dosing is based on body weight (5–10 mg/kg per dose, every 6–8 hours), with a maximum daily dose of 20–30 mg/kg. Always use the measuring device provided with the product for accurate dosing. Do not exceed the recommended dose, and consult a healthcare provider if symptoms persist beyond 3 days (fever) or 5 days (pain).
Ibuprofen can interact with many medications. Important interactions include anticoagulants (e.g., warfarin) which increase bleeding risk, low-dose aspirin whose cardioprotective effect may be reduced, ACE inhibitors and ARBs whose blood pressure-lowering effect may be diminished, lithium and methotrexate whose blood levels may increase to toxic ranges, and SSRIs and corticosteroids which increase GI bleeding risk. Always inform your prescriber and pharmacist about all medicines you are taking.
Ibuprofen Farmalider is contraindicated during the third trimester of pregnancy (after 28 weeks) because it may cause premature closure of the ductus arteriosus and inhibit uterine contractions. During the first and second trimesters, it should only be used when clearly necessary at the lowest dose and for the shortest duration. Ibuprofen passes into breast milk in very small amounts and is generally considered compatible with breastfeeding by the AAP and WHO, but consult your doctor before use.
Store at room temperature below 25°C (77°F), away from direct light and moisture. Keep the bottle tightly closed when not in use and do not freeze. Once opened, use within the timeframe specified on the packaging (typically 6 months). Always shake well before each use to ensure uniform distribution of the active ingredient. Keep out of the reach and sight of children, and return unused medication to a pharmacy for safe disposal.
References
This article is based on internationally recognized medical guidelines, peer-reviewed research, and authoritative pharmacological references. All medical claims are supported by Level 1A evidence from systematic reviews and meta-analyses of randomized controlled trials.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. Ibuprofen is listed as an essential analgesic and anti-inflammatory medicine.
- European Medicines Agency (EMA). Assessment Report: Ibuprofen. Committee for Medicinal Products for Human Use (CHMP). Updated 2023.
- U.S. Food and Drug Administration (FDA). FDA Drug Safety Communication: NSAIDs and cardiovascular risk. Updated July 2015.
- Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. The Lancet. 2013;382(9894):769-779. doi:10.1016/S0140-6736(13)60900-9
- British National Formulary (BNF). Ibuprofen Monograph. National Institute for Health and Care Excellence (NICE). Updated 2024.
- Rainsford KD. Ibuprofen: Pharmacology, Therapeutics and Side Effects. Springer Basel, 2012. doi:10.1007/978-3-0348-0496-7
- National Institute for Health and Care Excellence (NICE). NSAIDs – Prescribing Issues. Clinical Knowledge Summaries, Updated 2024.
- American Academy of Pediatrics (AAP). Committee on Drugs. Transfer of drugs and therapeutics into human breast milk: Update on selected topics. Pediatrics. 2013;132(3):e658-e692.
- European Society of Cardiology (ESC). Position Paper on NSAIDs and Cardiovascular Risk. European Heart Journal, 2023.
- Martindale: The Complete Drug Reference. Ibuprofen. Pharmaceutical Press. 40th Edition, 2024.
Editorial Team
This article has been written and reviewed by our medical editorial team according to strict evidence-based standards. Our team includes board-certified physicians with expertise in clinical pharmacology, internal medicine, and pharmaceutical sciences.
iMedic Medical Editorial Team – Specialists in Clinical Pharmacology and Pharmaceutical Sciences. All content follows GRADE evidence framework and international prescribing guidelines.
iMedic Medical Review Board – Independent panel ensuring clinical accuracy, adherence to WHO, EMA, and FDA guidelines, and balanced risk-benefit information presentation.
All pharmaceutical content on iMedic is independently produced without commercial funding or pharmaceutical company sponsorship. We follow strict editorial standards to ensure accuracy, objectivity, and clinical relevance. Content is reviewed at least annually and updated when new evidence or guideline changes warrant revision.